Hypertriglyceridemia

Metabolic·MeSH: Hypertriglyceridemia

14 drugs in development·8 companies·12 clinical trials

Drug Pipeline by Phase

Approved(5)

Drug	Company
fenofibrate	Amneal Pharmaceuticals, Inc. (AMRX)
vascepa	AMARIN CORP PLCUK (AMRN)
vascepa	AMARIN CORP PLCUK (AMRN)
VASCEPA (VAZKEPA in EU)	AMARIN CORP PLCUK (AMRN)
VASCEPA (VAZKEPA)	AMARIN CORP PLCUK (AMRN)

Phase 3(3)

Drug	Company
Pegozafermin	89bio, Inc. (ETNB)
plozasiran	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Plozasiran	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Phase 2(4)

Drug	Company
akcea-apociii-lrx	AKCEA THERAPEUTICS, INC. (AKCA)
ion775	IONIS PHARMACEUTICALS INC (IONS)
olezarsen	IONIS PHARMACEUTICALS INC (IONS)
Solbinsiran	ELI LILLY & Co (LLY)

Phase 1(1)

Drug	Company
ARO-APOC3	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Unknown(1)

Drug	Company
Omacor™	ABBOTT LABORATORIES (ABT)

BioSniper tracks 14 drugs in development for Hypertriglyceridemia across 8 companies.

There are 12 clinical trials targeting Hypertriglyceridemia tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.